Dr Shibu Joseph

Radiation Oncologist

MBBS, RANZCR, MD Radiotherapy, MRCP (UK)

Languages Spoken

English, Hindi, Malayalam

Special clinical interest

Neuro-oncology, uro-oncology, gynaecological cancer, haematological malignancies and sarcoma


Radiation therapy and Brachytherapy

Dr Shibu Joseph accepts referrals for all cancer types and is committed to delivering evidence-based and patient-centred cancer care. His honest and engaging approach to communication with his patients and their loved ones ensures that they are well-informed throughout all stages of their treatment journey.

Dr Joseph completed his Bachelor of Medicine, Bachelor of Surgery (MBBS) at India’s Calicut Medical College and undertook specialist oncology training in India, the United Kingdom and New Zealand. In 2016 Dr Joseph became a fellow of the Royal Australian and New Zealand College of Radiologists (RANZCR) after completing training in Hamilton, New Zealand.

Dr Joseph worked as a Consultant Clinical Oncologist at University Hospital of North Midlands and Christie Hospital, England 2016-2022.

Dr Joseph is a full time Radiation Oncologist between Riverina Cancer Care in Wagga and Cancer Care Griffith and is also covering clinics at Young.

Research, Awards and Teaching Interests

He maintains a special interest in clinical trials and treating benign conditions like Dupytruns contracture, Keloid, Heterotrophic Ossification with radiation therapy and gynaecological cancers with brachytherapy.


Dr Shibu Joseph has contributed to multiple publications with most recently being;

Efficacy of cabazitaxel second-line and beyond.

Salil VengalilEmma NolanNasira SultanaShibu JosephRajanee BhanaLoaie El-Helw– DOI: 10.1200/JCO.2020.38.6_suppl.226 Journal of Clinical Oncology 38, no. 6_suppl (February 20, 2020) 226-226.


Radium 223 treatment in metastatic prostate cancer: Exploring use of clinical factors for prognostication in routine practice.

Salil Vengalil, Paula Bee, Dawn Beetham, Rajanee Bhana, Shibu Joseph, Stephen Dainty, Ian Seedhouse, and Loaie El-Helw

Journal of Clinical Oncology 2020 38:15_suppl, e17550-e17550